<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04175132</url>
  </required_header>
  <id_info>
    <org_study_id>18124A</org_study_id>
    <nct_id>NCT04175132</nct_id>
  </id_info>
  <brief_title>Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)</brief_title>
  <official_title>Interventional, Open-label, Positron Emission Tomography (PET) Study With [11C]-PXT012253 Investigating the Brain mGlu4 Receptor Occupancy, Safety, Tolerability and Pharmacokinetics of Foliglurax in Healthy Subjects and Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to learn how foliglurax binds in regions of the brain&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To study binding of foliglurax to mGlu4 receptors in human brain, up to 9 healthy subjects&#xD;
      (Part A) and up to 8 patients with Parkinson's disease (Part B) will be injected with a&#xD;
      liquid dose of a radiolabelled tracer that allows measurement of foliglurax binding in the&#xD;
      brain to determine to which degree foliglurax binds to regions of the brain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    New efficacy data from another study&#xD;
  </why_stopped>
  <start_date type="Actual">November 12, 2019</start_date>
  <completion_date type="Actual">March 10, 2020</completion_date>
  <primary_completion_date type="Actual">March 3, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Receptor Occupancy (RO) on the metabotropic glutamate receptor 4 (mGlu4)</measure>
    <time_frame>From Day 1 up to Day 3</time_frame>
    <description>in Healthy Participants and in Patients With Parkinson's Disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C(PET) foliglurax</measure>
    <time_frame>From Day 1 up to Day 3</time_frame>
    <description>mean plasma concentration of foliglurax during PET measurement in Healthy Participants and in Patients With Parkinson's Disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC(0-24) foliglurax</measure>
    <time_frame>From Day 1 up to Day 3</time_frame>
    <description>Area under the plasma concentration curve from zero to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax foliglurax</measure>
    <time_frame>From Day 1 up to Day 3</time_frame>
    <description>Maximum observed plasma concentration of foliglurax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax foliglurax</measure>
    <time_frame>From Day 1 up to Day 3</time_frame>
    <description>Corresponding time (tmax) in plasma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PD patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>foliglurax</intervention_name>
    <description>Capsules of 20/80 mg foliglurax, orally. Single doses of 20-240 mg</description>
    <arm_group_label>Healthy subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>foliglurax</intervention_name>
    <description>Capsules of 20/80 mg foliglurax, orally. Single doses of 20-160 mg</description>
    <arm_group_label>PD patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Part A:&#xD;
&#xD;
          -  Healthy subjects&#xD;
&#xD;
          -  The subject has a normal structural MRI (sMRI) scan performed in the screening period,&#xD;
             as judged by the investigator.&#xD;
&#xD;
          -  The subject is, in the opinion of the investigator, generally healthy based on the&#xD;
             assessment of medical history, physical examination, vital signs, body weight, ECG,&#xD;
             and the results of the haematology, clinical chemistry, urinalysis, serology, and&#xD;
             other laboratory tests.&#xD;
&#xD;
          -  The subject can tolerate confined spaces for prolonged periods of time.&#xD;
&#xD;
          -  The subject is suitable for radial and/or brachial artery blood sampling and&#xD;
             cannulation.&#xD;
&#xD;
        Part B:&#xD;
&#xD;
          -  Patients with Parkinson's disease&#xD;
&#xD;
          -  The subject has a normal sMRI scan performed in the screening period, as judged by the&#xD;
             investigator.&#xD;
&#xD;
          -  The patient is, in the opinion of the investigator, fit for enrolment in the study&#xD;
             based on the assessment of medical history, physical examination, vital signs, body&#xD;
             weight, ECG, and the results of the haematology, clinical chemistry, urinalysis,&#xD;
             serology, and other laboratory tests.&#xD;
&#xD;
          -  The patient has been diagnosed with idiopathic Parkinson's disease for ≥3 years, with&#xD;
             a current disease severity of 2 to 4 on the modified Hoehn and Yahr scale in the OFF&#xD;
             state.&#xD;
&#xD;
          -  The patient has dyskinesia that is not too severe to cause discomfort for the patient&#xD;
             during PET imaging and predictable OFF time&#xD;
&#xD;
          -  In addition to the above criteria, the patient must, in the opinion of the&#xD;
             investigator, also be suitable for the study and the included PET imaging sessions.&#xD;
&#xD;
          -  The patient has been receiving a stable regimen of levodopa-containing therapy (total&#xD;
             levodopa dose ≤1600 mg per day) (≥3 doses per day of standard levodopa or ≥3 doses per&#xD;
             day of carbidopa and levodopa, sustained-release tablets or extended-release capsules&#xD;
             of carbidopa and levodopa or benserazide and levodopa), and be on a stable regimen of&#xD;
             permitted anti-Parkinsonian drugs (peripheral decarboxylase inhibitors, dopamine&#xD;
             agonists [except apomorphine], monoamine oxidase type B [MAO-B] inhibitors [except&#xD;
             safinamide], or catechol-O-methyl transferase [COMT] inhibitors) for ≥4 weeks prior to&#xD;
             foliglurax dosing&#xD;
&#xD;
          -  The patient can tolerate confined spaces for prolonged periods of time&#xD;
&#xD;
          -  The patient is suitable for radial and/or brachial artery blood sampling and&#xD;
             cannulation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has any concurrent disorder that may affect the particular target or&#xD;
             absorption, distribution, or elimination of the IMP&#xD;
&#xD;
        Other inclusion and exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

